KDR and neoplasm: The first, sorafenib, is a small molecule inhibitor of Raf kinase, VEGF receptor (VEGFR)-2 and -3 and platelet-derived growth factor (PDGF) tyrosine kinases that target tumor cell proliferation and angiogenesis [30,31].